Details of Disease

General Information of Disease (ID: DIS0BM1I)

Disease Name	Acute myeloid leukaemia
Synonyms	acute myeloid leukaemia; acute myeloid leukemia; unclassified acute myeloid leukemia; unclassified AML; acute myeloid leukemia not otherwise categorized; acute myeloid leukemia not otherwise specified; acute myeloid leukemia NOS; acute myeloid leukaemia NOS; acute myeloid leukemia, NOS; acute myeloid leukaemia not otherwise specified; AML, NOS; acute myeloid leukaemia not otherwise categorised; unclassified acute myeloid leukaemia
Disease Class	2A60: Acute myeloid leukaemia
Definition	Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.
Disease Hierarchy	DISCSPTN: Acute myelogenous leukaemia DIS0BM1I: Acute myeloid leukaemia
ICD Code	ICD-11 ICD-11: 2A60 ICD-9 ICD-9: 205 Expand ICD-9 205
Disease Identifiers	MONDO ID MONDO_0015667 UMLS CUI C5679583 MedGen ID 1842303 Orphanet ID 167714

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 20 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aclarubicin	DMLFZHD	Approved	Small molecular drug	[1]
ARN-509	DMT81LZ	Approved	Small molecular drug	[2]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[3]
Bestatin	DM8L9D4	Approved	Small molecular drug	[4]
Daunorubicin	DMQUSBT	Approved	Small molecular drug	[5]
DEOXYCYTIDINE	DMYE5LJ	Approved	Small molecular drug	[6]
ENASIDENIB MESYLATE	DMPOU5H	Approved	NA	[7]
Gemtuzumab ozogamicin	DMJ2O7B	Approved	Antibody	[8]
Gilteritinib	DMTI0ZO	Approved	Small molecular drug	[2]
Idarubicin	DMM0XGL	Approved	Small molecular drug	[9]
Ivosidenib	DM8S6T7	Approved	NA	[2]
Lestaurtinib	DMQ2AIJ	Approved (orphan drug)	Small molecular drug	[10]
Midostaurin	DMI6E0R	Approved	Small molecular drug	[11]
Motixafortide	DMW34B1	Approved	Peptide	[12]
Olutasidenib	DMPH916	Approved	NA	[13]
Quizartinib	DM8Y4JS	Approved	Small molecular drug	[14]
Tagraxofusp	DM9HQ5U	Approved	NA	[2]
Thioguanine	DM7NKEV	Approved	Small molecular drug	[15]
Tisagenlecleucel	DMM9BJD	Approved	CAR T Cell Therapy	[16]
Uracil mustard	DMHL7OB	Approved	Small molecular drug	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

This Disease is Treated as An Indication in 231 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
131I-labelled aCD45	DM3YEV0	Phase 3	Radiopharmaceutical therapy agent	[18]
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[3]
AG-221	DMS0ZBI	Phase 3	NA	[19]
AG-881	DMIE1WY	Phase 3	NA	[3]
AT-406	DMVJW0S	Phase 3	Small molecular drug	[20]
ATIR101	DMRV7T7	Phase 3	Cell therapy	[21]
BYM338	DM1ARHT	Phase 3	NA	[22]
CC-486	DMTNQB0	Phase 3	Small molecular drug	[3]
CP-868596	DMZIM37	Phase 3	Small molecular drug	[3]
CPI-0610	DMPXOYJ	Phase 3	NA	[3]
CPI-613	DM5XUQL	Phase 3	Small molecular drug	[23]
CPX-351	DM7BMAL	Phase 3	NA	[23]
DFP-10917	DM1WNGJ	Phase 3	Small molecular drug	[24]
Dociparstat sodium	DMQLSMB	Phase 3	NA	[25]
DSP-7888	DM781D6	Phase 3	Vaccine	[3]
Elesclomol	DMCE5DP	Phase 3	Small molecular drug	[26]
Galinpepimut-S	DMTEQEQ	Phase 3	NA	[27]
GMI-1271	DMDTGWQ	Phase 3	?	[28]
Hu5F9-G4	DMBER0Q	Phase 3	NA	[16]
Iomab-B	DMZA47Y	Phase 3	Antibody	[18]
Iomab-B CD45	DMGC0K9	Phase 3	NA	[3]
LMT-X	DMOFIBM	Phase 3	NA	[29]
Magrolimab	DMVXUR0	Phase 3	Antibody	[30]
PEG arginine deiminase	DMZSAUD	Phase 3	NA	[3]
Peginterferon lambda-1a	DMK6OFY	Phase 3	NA	[31]
PR1 peptide antigen vaccine	DMDB14Z	Phase 3	NA	[32]
Pracinostat	DMTD7AB	Phase 3	Small molecular drug	[23]
RG7388	DMF5GZI	Phase 3	Small molecular drug	[33]
Rydaptmidostaurin	DMLXOVD	Phase 3	NA	[3]
S-110	DMXY34J	Phase 3	NA	[34]
Sapacitabine	DM704AN	Phase 3	Small molecular drug	[35]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[23]
SGI110	DM1NQDW	Phase 3	NA	[34]
SNS-595	DMZE2JO	Phase 3	Small molecular drug	[36]
Tasisulam	DMJFRCT	Phase 3	Small molecular drug	[37]
Vadastuximab talirine	DM9LH10	Phase 3	NA	[16]
VAL-083	DM9J5Q4	Phase 3	Small molecular drug	[38]
Volasertib	DMOFH1M	Phase 3	Small molecular drug	[23]
Zarnestra	DMF30HL	Phase 3	Small molecular drug	[39]
CD123/CLL1 CAR-T Cells	DM45Z3P	Phase 2/3	CAR T Cell Therapy	[40]
CLL1 CAR-T Cell	DMUOMBZ	Phase 2/3	CAR T Cell Therapy	[40]
NLG8189	DM0798Z	Phase 2/3	Small molecular drug	[3]
Rivo-cel	DMXLS6K	Phase 2/3	Cell therapy	[41]
Actimab-A	DMKBIPR	Phase 2	NA	[16]
ADCT-301	DMY78E0	Phase 2	NA	[3]
AEB1102	DMB5CKZ	Phase 2	NA	[3]
ALRN-6924	DMLBWT1	Phase 2	NA	[3]
ALT-801	DM9KL7P	Phase 2	NA	[42]
ALT-803	DMK3U1X	Phase 2	NA	[43]
ALXN6000	DMH5LFR	Phase 2	Antibody	[16]
Anti-CD45 mAb 131I-BC8	DM26BMD	Phase 2	NA	[23]
AS-101	DMHBZXQ	Phase 2	Small molecular drug	[44]
AST-VAC1	DMYHV36	Phase 2	NA	[45]
AZD-4877	DMFVL5J	Phase 2	Small molecular drug	[46]
BGB-324	DMDI43Y	Phase 2	siRNA drug	[23]
BI 2536	DMJSADP	Phase 2	Small molecular drug	[47]
BI-836858	DMUVMY9	Phase 2	Antibody	[3]
BP-100-1-01	DMKDGI8	Phase 2	NA	[48]
BP1001	DMDUHIY	Phase 2	NA	[23]
BREQUINAR	DMKGM42	Phase 2	Small molecular drug	[49]
BST-236	DM00P8M	Phase 2	Small molecular drug	[50]
Cenersen	DMMN21R	Phase 2	Antisense drug	[51]
CHR-2797	DMULZ4W	Phase 2	Small molecular drug	[52]
CX-01	DMI9MLT	Phase 2	NA	[3]
Dilanubicel	DMW0HBJ	Phase 2	Cell therapy	[53]
DS-3201b	DMI69E5	Phase 2	Small molecular drug	[54]
ENMD-2076	DMJZVPB	Phase 2	Small molecular drug	[55]
Eryaspase	DMB3G81	Phase 2	NA	[3]
Ficlatuzumab	DMG65WH	Phase 2	Monoclonal antibody	[3]
Fipamezole	DMG439E	Phase 2	Small molecular drug	[56]
Flavopiridol	DMKSUOI	Phase 2	Small molecular drug	[23]
Flotetuzumab	DMVR6OM	Phase 2	NA	[57]
FPI-01	DMXOTMP	Phase 2	Vaccine	[58]
GO-203-2c	DMLWKZ7	Phase 2	NA	[3]
GRNVAC1	DMAHOEP	Phase 2	Vaccine	[59]
GS-9973	DMKWCTR	Phase 2	Small molecular drug	[3]
H3B-8800	DML2VSZ	Phase 2	NA	[3]
HTERT RNA vaccine	DM8OK0S	Phase 2	NA	[60]
Ifabotuzumab	DMGWNCJ	Phase 2	NA	[16]
IMG-7289	DML9AVG	Phase 2	NA	[3]
Inecalcitol oral	DMU5SZP	Phase 2	Small molecular drug	[3]
IPH-2102	DMPBR0D	Phase 2	NA	[61]
IRX-2	DMODLN7	Phase 2	NA	[62]
K-NK002	DMDUS54	Phase 2	Cell therapy	[63]
K562/GM-CSF	DMFFTC3	Phase 2	NA	[64]
Leukemia cancer vaccine	DMIFGLY	Phase 2	Vaccine	[65]
Leukemia DNA vaccine	DMZDU77	Phase 2	NA	[66]
Lirilumab	DMNGT89	Phase 2	Monoclonal antibody	[67]
Lomab B	DMW95IY	Phase 2	Monoclonal antibody	[68]
LOR-2040	DMX2TEM	Phase 2	NA	[69]
LY2090314	DMTBFE4	Phase 2	Small molecular drug	[70]
LY2523355	DMCV602	Phase 2	Small molecular drug	[71]
MB-102	DMLPNVS	Phase 2	NA	[16]
MK8242	DMRRHOB	Phase 2	NA	[72]
PCM-075	DMYFRTB	Phase 2	NA	[3]
phorbol 12-myristate 13-acetate	DMJWD62	Phase 2	Small molecular drug	[3]
PR104	DMZOM9G	Phase 2	Small molecular drug	[73]
Prexigebersen	DMGRJES	Phase 2	NA	[3]
PTX-200	DM0ZIT2	Phase 2	NA	[3]
Sodium butyrate	DMKNIVG	Phase 2	Small molecular drug	[74]
Talacotuzumab	DMARVFG	Phase 2	NA	[16]
WT1-targeted autologous dendritic cell vaccine	DMNFZYE	Phase 2	Vaccine	[75]
Zelenoleucel	DM0W5AZ	Phase 2	Cell therapy	[76]
Annamycin	DMDHJNV	Phase 1/2	Small molecular drug	[3]
ASP7517	DMW8OOC	Phase 1/2	Cell therapy	[77]
BPX-501	DMIMA4V	Phase 1/2	NA	[3]
BSK01	DM9S4SB	Phase 1/2	NA	[16]
CART-123 cells	DM0MCTJ	Phase 1/2	CAR T Cell Therapy	[78]
CD123-specific gene-engineered T cells	DMHOWU5	Phase 1/2	CAR T Cell Therapy	[79]
CD33-specific gene-engineered T cells	DMM35D2	Phase 1/2	CAR T Cell Therapy	[79]
CD38-specific gene-engineered T cells	DMCH98G	Phase 1/2	CAR T Cell Therapy	[79]
CD56-specific gene-engineered T cells	DM35XCT	Phase 1/2	CAR T Cell Therapy	[79]
CG-806	DMPYW28	Phase 1/2	Small molecular drug	[80]
CIK-CAR.CD19	DMQWCIX	Phase 1/2	NA	[3]
CLL1-specific gene-engineered T cells	DMCT917	Phase 1/2	CAR T Cell Therapy	[79]
CNDO-109	DMQ5E8L	Phase 1/2	NA	[23]
CWP232291	DMBUYIK	Phase 1/2	Small molecular drug	[81]
DT388IL-3	DMRXQCL	Phase 1/2	NA	[82]
EPZ-5676	DMN2FS3	Phase 1/2	Small molecular drug	[83]
FF-10101	DM1XIMU	Phase 1/2	Small molecular drug	[84]
FF-10501-01	DM0HSJK	Phase 1/2	NA	[3]
G0-203-2c	DMG48WN	Phase 1/2	NA	[85]
HM43239	DMV1SDA	Phase 1/2	Small molecular drug	[86]
HuM-195-Ac-225	DMIU1HY	Phase 1/2	NA	[87]
INCB59872	DMRLV7G	Phase 1/2	NA	[3]
JTCR016	DM3PJZH	Phase 1/2	NA	[16]
KO-539	DM0NZYC	Phase 1/2	Small molecular drug	[88]
Lintuzumab Ac-225	DM7QHXA	Phase 1/2	Monoclonal antibody	[89]
MG7-CART	DME6PB0	Phase 1/2	CAR T Cell Therapy	[90]
Muc1-specific gene-engineered T cells	DMPNR0J	Phase 1/2	CAR T Cell Therapy	[79]
NEXI-001	DMLQTC9	Phase 1/2	Cell therapy	[91]
ONO-7475	DMV6GX7	Phase 1/2	Small molecular drug	[3]
OTX-015	DMI8RG1	Phase 1/2	Small molecular drug	[92]
OXi4503	DM8133S	Phase 1/2	Small molecular drug	[3]
PLX2853	DMX168L	Phase 1/2	Small molecular drug	[93]
PRI-724	DM0HTEF	Phase 1/2	NA	[94]
RhH1.3	DMD5G2F	Phase 1/2	NA	[95]
RTX-240	DMBL7FH	Phase 1/2	Cell therapy	[96]
SAR440234	DM6M8O4	Phase 1/2	Antibody	[97]
SEL-24	DMH064K	Phase 1/2	NA	[3]
SEL24	DMD37Q5	Phase 1/2	Small molecular drug	[98]
SGN-CD33A	DMRC7PI	Phase 1/2	Antibody	[23]
SL-401	DMOCHVE	Phase 1/2	NA	[99]
225Ac-labelled aCD33	DM2SQBF	Phase 1	Radiopharmaceutical therapy agent	[100]
AB-110	DM0F520	Phase 1	Cell therapy	[101]
ABBV-184	DM71Q69	Phase 1	TCR-T cell therapy	[102]
ABBV-744	DMTEA9C	Phase 1	NA	[3]
AGS-67E	DM78KH5	Phase 1	NA	[16]
AGS62P1	DMZMHTA	Phase 1	NA	[3]
AMG 176	DM0Q7NO	Phase 1	NA	[103]
AMG 330	DMC3G2E	Phase 1	Antibody	[3]
AMG 427	DMI7JO6	Phase 1	Antibody	[104]
AMG 673	DMA3B9T	Phase 1	Antibody	[3]
AMV564	DMT27PA	Phase 1	NA	[3]
Anti-CD33	DM43VLG	Phase 1	NA	[3]
Anti-CEA CAR-T cells	DMA7L3O	Phase 1	CAR T Cell Therapy	[105]
APVO436	DMUAMZY	Phase 1	Antibody	[106]
AVB-S6-500	DMKCRMD	Phase 1	NA	[3]
BAY1436032	DMPNBJ1	Phase 1	NA	[3]
BB-MPI-03	DM0PII2	Phase 1	NA	[45]
BGB-11417	DM7QTIC	Phase 1	Small molecular drug	[107]
BI-811283	DMNUY32	Phase 1	NA	[108]
BMS-936564	DMS4H1J	Phase 1	NA	[109]
BPX-701	DMYERSD	Phase 1	NA	[16]
CART-117 cells	DMAKZTW	Phase 1	CAR T Cell Therapy	[110]
CART-33 cells	DMBHCSL	Phase 1	CAR T Cell Therapy	[110]
CART-34 cells	DMRNIB9	Phase 1	CAR T Cell Therapy	[110]
CART-38 cells	DMKN8XD	Phase 1	CAR T Cell Therapy	[110]
CART-56 cells	DMQTOBF	Phase 1	CAR T Cell Therapy	[110]
CART-Muc1 cells	DMOJEXG	Phase 1	CAR T Cell Therapy	[110]
CART123 cells	DMD0XWR	Phase 1	CAR T Cell Therapy	[111]
CB-5339	DMOXDIY	Phase 1	Small molecular drug	[112]
CC-90002	DMK0QDO	Phase 1	Antibody	[16]
CC-90009	DMZTLOD	Phase 1	NA	[3]
CD123-CD33 Ccar	DMUJF9T	Phase 1	CAR T Cell Therapy	[113]
CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells	DMDFY1R	Phase 1	CAR T Cell Therapy	[114]
CD33-CAR-T Cell	DMYD31U	Phase 1	CAR T Cell Therapy	[115]
CLL1-CD33 cCART cell therapy	DM5EM04	Phase 1	CAR T Cell Therapy	[116]
CLT030	DM674MP	Phase 1	Antibody drug conjugate	[117]
CM-CS1 T-cell	DMY5V4U	Phase 1	CAR T Cell Therapy	[118]
CSL-362	DMO97RV	Phase 1	Antibody	[119]
CYAD-02	DM6EPP8	Phase 1	CAR T Cell Therapy	[120]
CYC140	DMC6PKJ	Phase 1	Small molecular drug	[121]
DCLL9718S	DMTIWM4	Phase 1	NA	[3]
DS-3201	DMRLPFG	Phase 1	NA	[3]
FATE-NK100	DMT8WXM	Phase 1	NA	[3]
FF-10101-01	DMS1O56	Phase 1	NA	[3]
FT500	DMA18BH	Phase 1	Cell therapy	[122]
FT538	DMV20B8	Phase 1	Cell therapy	[123]
GDX012	DM76WSW	Phase 1	Cell therapy	[124]
GEM333	DMDMKVL	Phase 1	Antibody	[125]
GSK-2130579A	DMRXW9P	Phase 1	Vaccine	[126]
IGN523	DM1MY26	Phase 1	Antibody	[127]
IM23	DML5O7T	Phase 1	CAR T Cell Therapy	[128]
IMC-EB10	DMCZQNJ	Phase 1	Antibody	[129]
IMGN779	DMP9FWB	Phase 1	NA	[3]
INNO-305	DMG6S8U	Phase 1	NA	[130]
IO-202	DMU03WD	Phase 1	Antibody	[131]
JNJ-63709178	DM5SZAK	Phase 1	Antibody	[3]
JNJ-67571244	DMQOHRA	Phase 1	Antibody	[132]
KITE-222	DMPF49Z	Phase 1	CAR-T cell therapy	[133]
KW-2449	DMFO7RP	Phase 1	Small molecular drug	[134]
LAM-003	DMQHWMJ	Phase 1	NA	[3]
LC-1	DMJEACT	Phase 1	NA	[135]
LP-108	DMYIXQZ	Phase 1	NA	[136]
MIK665	DMTUVCG	Phase 1	Small molecular drug	[137]
Mivebresib	DMCPF90	Phase 1	NA	[3]
NKR-2 CAR-T Cells	DMDLJM1	Phase 1	CAR T Cell Therapy	[138]
NKR-2 cells	DMR5ATX	Phase 1	CAR T Cell Therapy	[139]
NKX101	DMHJ1Y0	Phase 1	CAR T Cell Therapy	[140]
OTSSP167	DMF5KNO	Phase 1	Small molecular drug	[3]
PF-06747143	DM2ZJ1C	Phase 1	NA	[16]
PNK-007	DMI344Y	Phase 1	NA	[16]
PRGN-3006	DMNAB57	Phase 1	CAR-T cell therapy	[141]
RG6007	DMLGQJR	Phase 1	Bispecific antibody	[142]
RG7775	DMXBS6U	Phase 1	NA	[143]
SAR-103168	DMUZXTA	Phase 1	NA	[144]
SAR443579	DMF8W8F	Phase 1	Antibody	[145]
SAR445419	DMMWZFV	Phase 1	Cell therapy	[146]
SEA-CD70	DMX94YF	Phase 1	Antibody	[147]
SEL120	DMHCUZV	Phase 1	Small molecular drug	[148]
SGN-CD123A	DMRC0PJ	Phase 1	NA	[3]
SKI-G-801	DM4I92Z	Phase 1	Small molecular drug	[149]
SY-1425	DMH8UF0	Phase 1	NA	[3]
TAS-1440	DMHIA7Y	Phase 1	Small molecular drug	[150]
TCN-P	DMV0AH8	Phase 1	Small molecular drug	[151]
UCART123	DMG7FLI	Phase 1	CAR T Cell Therapy	[3]
VOB560	DMDG30Q	Phase 1	Small molecular drug	[152]
XmAb14045	DMSVB1Y	Phase 1	NA	[3]
CAR-T cells targeting CD38	DMH5C37	Clinical trial	CAR T Cell Therapy	[153]
CAR-T cells targeting CD56	DMAK1ME	Clinical trial	CAR T Cell Therapy	[153]
------------------------------------------------------------------------------------


⏷ Show the Full List of 231 Drug(s)

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LY335979	DM2KITF	Discontinued in Phase 3	Small molecular drug	[154]
Valspodar	DMXRU9M	Discontinued in Phase 3	Small molecular drug	[155]
CER-227185	DMMZ79C	Discontinued in Phase 1/2	NA	[156]
HuM-195-Bi-213	DM9AOJT	Discontinued in Phase 1/2	NA	[157]
Lintuzumab Bi-213	DMF21HS	Discontinued in Phase 1/2	Monoclonal antibody	[157]
CEP-4186	DMZE0SJ	Terminated	NA	[161]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 9 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes	DMYZ3O9	Phase 0	CAR T Cell Therapy	[158]
2-D08	DMRDQPT	Preclinical	Small molecular drug	[159]
ATA2321	DMRLHC8	Preclinical	CAR T Cell Therapy	[160]
CAR-T cells targeting CD117	DM9HG6S	Preclinical	CAR T Cell Therapy	[153]
CAR-T cells targeting CD123	DMSZNQE	Preclinical	CAR T Cell Therapy	[153]
CAR-T cells targeting CD133	DMYOR5T	Preclinical	CAR T Cell Therapy	[153]
CAR-T cells targeting CD33	DMH7BT9	Preclinical	CAR T Cell Therapy	[153]
CAR-T cells targeting CD34	DM3G0OP	Preclinical	CAR T Cell Therapy	[153]
CAR-T cells targeting Mucl	DMA1BLC	Preclinical	CAR T Cell Therapy	[153]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

This Disease is Treated as An Indication in 9 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AC-501	DM0KONX	Investigative	NA	[162]
AKN-028	DMANYU5	Investigative	Small molecular drug	[163]
Anti-CD44 mab	DMAN19P	Investigative	Monoclonal antibody	[162]
BI 7273	DMI3ANC	Investigative	Small molecular drug	[164]
CG-1255	DM2KXMB	Investigative	NA	[162]
COTI-001	DM0XL17	Investigative	NA	[162]
Rebelex	DMGSIXO	Investigative	NA	[162]
SB-559457	DM0OLYF	Investigative	NA	[165]
VLIM-88	DM691GO	Investigative	NA	[162]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5151).
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6775).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
12	ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
13	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215814.
14	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216993
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6845).
16	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
18	ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT02273739) Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation. U.S.National Institutes of Health.
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
21	ClinicalTrials.gov (NCT02999854) Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY). U.S. National Institutes of Health.
22	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8086).
23	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24	ClinicalTrials.gov (NCT03926624) Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage. U.S. National Institutes of Health.
25	ClinicalTrials.gov (NCT04571645) Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML). U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT00522834) Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT04229979) GPS Compared With BAT in AML CR2/CR2p. U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT03616470) Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
29	ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT04778397) Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2). U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT01866930) Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naive Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. U.S. National Institutes of Health.
32	Therapeutic Vaccines against Cancer: Clinical trials of therapeutic vaccines in cancer patients yield positive results. OncoLog, August 2010, Vol.55, No.8.
33	ClinicalTrials.gov (NCT02545283) A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (MIRROS). U.S. National Institutes of Health.
34	ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
35	ClinicalTrials.gov (NCT01303796) A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT01191801) Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (VALOR). U.S. National Institutes of Health.
37	ClinicalTrials.gov (NCT01006252) A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma. U.S. National Institutes of Health.
38	ClinicalTrials.gov (NCT01478178) Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
39	ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
40	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
41	ClinicalTrials.gov (NCT03699475) Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE). U.S. National Institutes of Health.
42	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
43	ClinicalTrials.gov (NCT03050216) QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML. U.S. National Institutes of Health.
44	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 437).
45	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
46	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7708).
47	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5666).
48	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
49	ClinicalTrials.gov (NCT03760666) A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
50	ClinicalTrials.gov (NCT04827719) BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS. U.S. National Institutes of Health.
51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8270).
52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022187)
53	ClinicalTrials.gov (NCT03301597) NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH). U.S. National Institutes of Health.
54	ClinicalTrials.gov (NCT03110354) DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). U.S. National Institutes of Health.
55	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7885).
56	ClinicalTrials.gov (NCT00559871) Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease. U.S. National Institutes of Health.
57	ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
58	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040574)
59	ClinicalTrials.gov (NCT00510133) A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
60	Clinical pipeline report, company report or official report of Asterias.
61	ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
62	ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
63	ClinicalTrials.gov (NCT04395092) Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). U.S. National Institutes of Health.
64	ClinicalTrials.gov (NCT00363649) Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI. U.S. National Institutes of Health.
65	ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
66	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
67	ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
68	Iomab-B for Hematopoetic Stem Cells Transplantation. Pipeline report of Actinium Pharmaecuticals. 2012.
69	ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
70	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7958).
71	ClinicalTrials.gov (NCT01416389) A Study of LY2523355 in Patients With Breast Cancer. U.S. National Institutes of Health.
72	ClinicalTrials.gov (NCT01463696) Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650). U.S. National Institutes of Health.
73	ClinicalTrials.gov (NCT00544674) PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer. U.S. National Institutes of Health.
74	The enhancement of phase 2 enzyme activities by sodium butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53. Mol Cell Biochem. 2012 Nov;370(1-2):7-14.
75	ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
76	ClinicalTrials.gov (NCT04511130) A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation. U.S.National Institutes of Health.
77	ClinicalTrials.gov (NCT04079296) A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
78	ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
79	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
80	ClinicalTrials.gov (NCT04477291) A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
81	ClinicalTrials.gov (NCT03055286) Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. U.S. National Institutes of Health.
82	ClinicalTrials.gov (NCT00397579) DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes. U.S. National Institutes of Health.
83	ClinicalTrials.gov (NCT03701295) Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement. U.S. National Institutes of Health.
84	ClinicalTrials.gov (NCT03194685) Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
85	Clinical pipeline report, company report or official report of Genus 0ncology.
86	ClinicalTrials.gov (NCT03850574) Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
87	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
88	ClinicalTrials.gov (NCT04067336) First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
89	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017917)
90	ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
91	ClinicalTrials.gov (NCT04284228) Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT. U.S. National Institutes of Health.
92	ClinicalTrials.gov (NCT02303782) A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT). U.S. National Institutes of Health.
93	ClinicalTrials.gov (NCT04493619) PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. U.S. National Institutes of Health.
94	ClinicalTrials.gov (NCT01606579) Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. U.S. National Institutes of Health.
95	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021304)
96	ClinicalTrials.gov (NCT04372706) RTX-240 Monotherapy. U.S. National Institutes of Health.
97	ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
98	ClinicalTrials.gov (NCT03008187) SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
99	ClinicalTrials.gov (NCT02113982) SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia. U.S. National Institutes of Health.
100	ClinicalTrials.gov (NCT03705858) Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
101	ClinicalTrials.gov (NCT03483324) Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation. U.S. National Institutes of Health.
102	ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health.
103	ClinicalTrials.gov (NCT03797261) A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
104	ClinicalTrials.gov (NCT03541369) Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528). U.S. National Institutes of Health.
105	ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
106	ClinicalTrials.gov (NCT03647800) Study of APVO436 in Patients With AML or MDS. U.S. National Institutes of Health.
107	ClinicalTrials.gov (NCT04771130) A Study of BGB-11417 in Participants With Myeloid Malignancies. U.S. National Institutes of Health.
108	ClinicalTrials.gov (NCT00701324) BI 811283 in Various Solid Tumours. U.S. National Institutes of Health.
109	ClinicalTrials.gov (NCT02305563) Phase 1 Study of BMS-936564. U.S. National Institutes of Health.
110	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
111	ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML
112	ClinicalTrials.gov (NCT04402541) Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
113	ClinicalTrials.gov (NCT04156256) CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies. U.S. National Institutes of Health.
114	ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
115	ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
116	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
117	CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749.
118	ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
119	ClinicalTrials.gov (NCT01632852) A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission. U.S. National Institutes of Health.
120	ClinicalTrials.gov (NCT04167696) Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1). U.S. National Institutes of Health.
121	ClinicalTrials.gov (NCT03884829) A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS. U.S. National Institutes of Health.
122	ClinicalTrials.gov (NCT03841110) FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
123	ClinicalTrials.gov (NCT04614636) FT538 in Subjects With Advanced Hematologic Malignancies. U.S. National Institutes of Health.
124	ClinicalTrials.gov (NCT05001451) A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia. U.S.National Institutes of Health.
125	ClinicalTrials.gov (NCT03516760) Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
126	ClinicalTrials.gov (NCT01051063) Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy. U.S. National Institutes of Health.
127	ClinicalTrials.gov (NCT02040506) A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. U.S. National Institutes of Health.
128	ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
129	ClinicalTrials.gov (NCT00887926) Study of EB10 in Patients With Leukemia. U.S. National Institutes of Health.
130	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
131	ClinicalTrials.gov (NCT04372433) IO-202 as Monotherapy in Patients in AML and CMML. U.S. National Institutes of Health.
132	ClinicalTrials.gov (NCT03915379) A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
133	ClinicalTrials.gov (NCT04789408) A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S.National Institutes of Health.
134	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5691).
135	A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494.
136	ClinicalTrials.gov (NCT04139434) Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
137	ClinicalTrials.gov (NCT02979366) Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
138	ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
139	ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
140	ClinicalTrials.gov (NCT04623944) NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS. U.S. National Institutes of Health.
141	ClinicalTrials.gov (NCT03927261) A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome. U.S.National Institutes of Health.
142	Clinical pipeline report, company report or official report of Roche
143	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040360)
144	ClinicalTrials.gov (NCT00981240) Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes. U.S. National Institutes of Health.
145	ClinicalTrials.gov (NCT05086315) An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). U.S.National Institutes of Health.
146	ClinicalTrials.gov (NCT05712278) A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). U.S.National Institutes of Health.
147	ClinicalTrials.gov (NCT04227847) A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies. U.S. National Institutes of Health.
148	ClinicalTrials.gov (NCT04021368) SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
149	ClinicalTrials.gov (NCT03564288) Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
150	ClinicalTrials.gov (NCT04282668) A Study of TAS1440 With ATRA in Subjects With r/r AML. U.S. National Institutes of Health.
151	ClinicalTrials.gov (NCT00363454) Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer. U.S. National Institutes of Health.
152	ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
153	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
154	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005159)
155	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001281)
156	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026293)
157	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008571)
158	ClinicalTrials.gov (NCT02623582) CD123 Redirected Autologous T Cells for AML
159	2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochem Biophys Res Commun. 2019 Jun 11;513(4):1063-1069.
160	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
161	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012493)
162	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
163	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7969).
164	Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.
165	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).